Navigation Links
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Date:9/4/2012

NEW YORK, Sept. 4, 2012  /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.  All shares of the common stock to be sold in the offering will be offered by Intercept.  The number of shares to be offered and the price range for the offering have not yet been determined.

BofA Merrill Lynch is acting as sole book-running manager for the offering.  BMO Capital Markets is acting as lead manager and Needham & Company, LLC, Wedbush PacGrow Life Sciences and ThinkEquity LLC are acting as co-managers. 

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, and there shall not be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from BofA Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or via email, at dg.prospectus_requests@baml.com, or BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square New York, NY 10036, Telephone: (800) 414-3627 E-mail: bmoprospectus@bmo.com.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. PBC is a chronic autoimmune liver disease that may progress to cirrhosis and liver failure, and it is currently the fifth leading indication for liver transplant in the United States. OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has outlicensed the product candidate to Dainippon Sumitomo Pharma (DSP).

 


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercept Pharmaceuticals Closes $30 Million Series C Financing
2. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
3. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
4. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
6. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
7. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
8. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
9. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
10. Global RFID in Healthcare and Pharmaceuticals Industry
11. Isis Pharmaceuticals to Present at the 2012 Stifel Nicolaus Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... India , February 10, 2016 ... a new market research report "Pharmaceutical Packaging Equipment Market ... Wrapping, Labeling & Serialization), by Product Type (Tablet, Powder, ... 2020", published by MarketsandMarkets, studies the global market during the ... expected to grow at a CAGR of 6.9% during ...
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... United ... Nesbitt as the latest addition to its growing list of Partner Firms. ... the Southeast, from Orlando to Huntsville and in between. , Harnessing the experience ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & Science, ... stainless steel (PLS) columns combine the strength of traditional stainless steel with the ... biological samples while operating at ultra-high pressures of 20,000 psi. The higher operating ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Anxiety of older ... the start of Medicare Part D a decade ago, according to The Senior ... older adults on how they are coping with rapidly rising costs. “The implications ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... the cause of injury may be one of many possible sources: sports, car ... Continuing Education Course , Mastering Rehab Solutions for the Complexities of Concussions ...
Breaking Medicine News(10 mins):